



# CEO & INVESTOR CONFERENCE

**February 10-11, 2020 • New York, NY**

New York Marriott Marquis



***Partnering activity is up 36%***

*41 new companies AND investors already in the system this year!*

**#BIOCEO20 • [bio.org/CEO](https://bio.org/CEO)**





# CEO & INVESTOR CONFERENCE

Returning for its 22nd year, the **BIO CEO & Investor Conference** is one of the only independent East-Coast partnering events dedicated to showcasing the hottest clinical developments that are ready for their next stage of development. This year's event will attract 1,200+ attendees, including more than 650 early-stage and institutional investors focused on accelerating the progress of both therapeutic technologies and molecular diagnostics into commercialization and helping patients.

## Why Attend?

- **EXPERIENCE** the best of biotech with two-days of productive partnering meetings with institutional investors, industry analysts, and senior biotechnology executives, in one location.
- **HEAR** Washington's perspective on policy and other timely developments affecting the industry.
- **EVALUATE** fresh investment opportunities including compatible, complementary, and competitive companies.
- **LEARN** about the hottest clinical developments and industry catalysts by attending the conference's therapeutic and business-focused panel discussions.
- **ATTEND** fireside chats with senior business leaders who will share their recent company successes, what keeps the C-suite up at night, and where the industry's leading companies are headed in 2020.
- **GAIN** access to BIO One-on-One Partnering™ for scouting potential investments and deal partners, optimizing your time at the event.
- **UNIQUE PLATFORM** for your company to highlight accomplishments and discuss upcoming milestones. Approximately 150 companies will be chosen based on a selection process evaluating a company's pipeline and R&D activities.
- **GET THE PULSE** of the current and proposed investment trends in biotechnology.
- **NETWORK** with peers, investors, and potential partners attending the conference and our exclusive receptions.
- **EXCLUSIVE** sponsorship opportunities to showcase thought leadership, elevate brand identity and maximize partnering benefits with an elite audience.



# 2020 Agenda

Visit [bio.org/ceo](https://bio.org/ceo) for the latest schedule of events.  
Sessions, speakers, and presentations are subject to change.

## MONDAY, FEBRUARY 10

- 8:45 AM – 9:00 AM** *Welcome and Update on BIO's 2020 Initiatives on Behalf of the Industry*  
*Jeremy M. Levin, D.Phil, MB BChir, CEO, Ovid Therapeutics Inc. and Chairman of the Board, BIO*
- 9:00 AM – 4:30 PM** *Company Presentations*
- 9:00 AM – 9:55 AM** *Expanding the Toolkit for Fighting Solid Tumors*
- 10:00 AM – 10:55 AM** *Fireside Chat: Carol Lynch, President of Sandoz US and Head of North America, Sandoz, a Novartis division*
- 11:00 AM – 11:55 AM** *Commercialization Strategies for Communicating Evidence of a Therapy's Value*
- 1:30 PM – 2:25 PM** *Preparing for NASH and Other New Liver Treatments*
- 2:30 PM – 3:25 PM** *Election Outlook—Explaining Healthcare Policy Proposals' Impacts on Innovation and Patients*
- 3:30 PM – 4:25 PM** *Advances in Gene Therapy: Facing Challenges and Adapting for the Future*
- 4:30 PM – 5:45 PM** *Shifting Tides: A Wall Street Perspective on Biotech Deal-Making in the Current Global Climate*
- 6:00 PM – 7:00 PM** *Welcome Reception*

## TUESDAY, FEBRUARY 11

- 8:30 AM – 8:55 AM** *Navigating the New CFIUS Regulations for Investments with U.S. Partners*
- 9:00 AM – 3:45 PM** *Company Presentations*
- 9:00 AM – 9:55 AM** *Exploring Innovation in Cardiovascular Disease Therapeutics*
- 10:00 AM – 10:55 AM** *Fireside Chat: Barbara Dalton, PhD, Vice President, WWBD and Senior Managing Partner of Pfizer Ventures, Pfizer*
- 11:00 AM – 11:55 AM** *Fireside Chat: Ted W. Love, MD, President and Chief Executive Officer, Global Blood Therapeutics*
- 12:00 PM – 12:55 PM** *Fireside Chat: Evan Loh, MD, Chief Executive Officer, Paratek Pharmaceuticals*
- 1:00 PM – 1:55 PM** *Industry Approaches for Hiring and Developing an Inclusive Workforce*
- 2:00 PM – 2:55 PM** *Fireside Chat: Michael M. Morrissey, PhD, President and Chief Executive Officer, Exelixis*
- 3:00 PM – 3:55 PM** *Neuroscience at the Crossroads: Late Stage Brain Disorder Pipelines and Unmet Needs*
- 4:00 PM – 4:55 PM** *Market Outlook—Market Performance and IPO Class of 2020*



MONDAY, FEBRUARY 10, 2020

► **Welcome and Update on BIO's 2020 Initiatives on Behalf of the Industry**

8:45-9:00 AM

**Jeremy M. Levin, D.Phil, MB BChir, CEO, Ovid Therapeutics Inc. and Chairman of the Board, BIO**

► **Expanding the Toolkit for Fighting Solid Tumors**

9:00-9:55 AM

As PD-1/L1 checkpoint inhibitors continue to reveal new tumor types those drugs can attack successfully, more than 2,000 combination trials have launched to attempt to enhance those inhibitors' effects. However, exciting approaches in other mechanisms of action are also expanding our understanding of solid tumors, the tumor microenvironments, and the opportunities to disrupt tumor growth and help cancer patients. This panel will explore the breadth of the tumor-fighting pipelines and those clinical benefits likely to be realized soonest.

**MODERATOR:** **Asthika Goonewardene**, *Managing Director, Senior Biotechnology Analyst, SunTrust Robinson Humphries*

**PANELISTS:** **Benjamin Cowen, MBA, PhD**, *CEO, ImmunoMet Therapeutics*  
**Natalie Sacks, MD**, *Chief Medical Officer, Harpoon Therapeutics*  
**Mary Szela**, *CEO and President, TriSalus Life Sciences*  
**Mary Tagliaferri, MD**, *Chief Medical Officer, Nektar Therapeutics*



## Fireside Chat

10:00-10:55 AM



**Carol Lynch**  
*President of Sandoz US and Head of North America, Sandoz, a Novartis division*



**Moderator Rob Wright**  
*Chief Editor, Life Science Leader*





## ► **Commercialization Strategies for Communicating Evidence of a Therapy's Value**

**11:00-11:55 AM**

Small and mid-sized biotech companies commercially launched 42% of U.S. new drug approvals in 2018, quadrupling their share from a decade prior compared with older global pharmaceutical companies, according to IQVIA Institute analysis. As these emerging biotechs pursue commercial independence, leadership teams must learn to make compelling value reimbursement arguments, negotiate with payers, and form skilled sales teams. This panel will discuss how to develop such capabilities in alignment with R&D efforts and the Real World Evidence-based resources that might support such strategies.

**MODERATOR:** **Lydia Ramsey**, *Correspondent, Business Insider*

**PANELISTS:** **Aofie Brennan, MB, CHB**, *President and CEO, Synlogic*  
**Carolyn Magill**, *CEO, Aetion*  
**Jing L. Marantz, MD, PhD, SVP**, *Head of Medical Affairs, Alnylam Pharmaceuticals*  
**Stacey D. Seltzer**, *Partner, Aisling Capital*  
**Shawn Tomasello**, *Corporate Board Director, Urogen, Pharma, Inc.*

## ► **Preparing for NASH and Other New Liver Treatments**

**1:30-2:25 PM**

Approximately 5% of people in the U.S. are at risk for NASH and it is on track to be the dominant disease causing liver failure—but no therapeutic medicines have yet been approved. More than 50 companies are positioning for a stake of providing treatments to patients in an expected \$35B market by 2025. With high profile target failures in bile acid receptors and caspases, companies are finding opportunities in combination therapies, new targets, and diversifying the risks by testing potential targets with other liver diseases. Hear from a panel of industry insiders on the competitive landscape for NASH and how progress and setbacks there are affecting liver treatment development broadly.

**MODERATOR:** **Yasmeen Rahimi, PhD**, *Managing Director & Senior Research Analyst, Co-Head of Biotechnology Research, ROTH Capital Partners*

**PANELISTS:** **Morris J. Birnbaum**, *Senior Vice President and Chief Scientific Officer for the Internal Medicine Research Unit, Pfizer*  
**Roger Green**, *Founder and CEO, RGA Consulting*  
**Scott L. Friedman, MD**, *Dean for Therapeutic Discovery and Chief, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai*  
**Pascal Prigent**, *Chief Executive Officer, GENFIT*  
**Mark Pruzanski, MD**, *President, CEO, and Director, Intercept Pharmaceuticals*  
**David J. Woodhouse, PhD**, *CEO, NGM Biopharmaceuticals*



## ► Election Outlook—Explaining Healthcare Policy Proposals' Impacts on Innovation and Patients

2:30-3:25 PM

Polls of U.S. public confidence in prescription drug companies have dropped so far that multiple policy proposals are under consideration that could drastically shrink the investment resources available for innovative medicines, reducing patients' hopes and raising healthcare costs long-term. Such proposals intersect during an election year likely to be highly volatile as political matters unrelated to healthcare also impact candidates, legislative calendars, and regulatory priorities. This panel will explain and prioritize the policy proposals with greatest impact on biopharmas as well as discuss the opportunities for the industry to communicate the risks of bad policies on pipelines and patients.

**MODERATOR:** **Brian Rye**, Senior Healthcare Policy Analyst, Bloomberg Intelligence

**PANELISTS:** **Sarah Butler Donovan**, Head, Client Solutions, Marketing & Ops, Avalere Health  
**James C. Greenwood**, President and CEO, Biotechnology Innovation Organization (BIO)  
**Paul Hastings**, CEO, Nkarta Therapeutics  
**Susan Peschin**, President and Chief Executive Officer, Alliance for Aging Research  
**Peter Pitts**, President and Co-Founder, Center for Medicine in the Public Interest


## ► Advances in Gene Therapy: Facing Challenges and Adapting for the Future

3:30-4:25 PM

Fewer than 20 gene therapies have so far been approved in the global market. With more than 750 under development, our future invites us to reap promising benefits as the field forges on, further substantiating this exciting new modality. Despite all the clinical progress, several challenges remain: almost all gene therapies approved and currently under development cluster in narrow indications for rare diseases, reaching relatively small patient populations; manufacturing continues to be costly; and high reimbursement amounts concern healthcare payers and patients. Hear from leaders in this field as they share their lessons learned and thoughts on the path forward to ensure gene therapies expand their reach to treat more patients on the road to cures.

**MODERATOR:** **Amanda Murphy**, Managing Director, Research (Biotechnology), BTIG

**PANELISTS:** **Asa Abeliovich, MD, PhD**, CEO and Founder, Prevail Therapeutics  
**Vered Caplan**, Chief Executive Officer and Director, Orgenesis  
**Kuldeep Neote, PhD**, Vice President, External Innovation, Eli Lilly and Company



### Did you know?

**2020 BIO CEO has a record share of private company investors.**



## ► ***Shifting Tides: A Wall Street Perspective on Biotech Deal-Making in the Current Global Climate***

**4:30-5:45 PM**

Despite a record number of large deals across the pharmaceutical and biotechnology landscape, market indicators are pointing toward a noticeable shift in the appetite for global deal-making across the industry. As the pool of high-valued assets becomes smaller, will signs point to a drastic increase in smaller deals for larger pharma companies looking to solidify their balance sheets across core therapeutic areas? How does a strong public market with a well-capitalized pool of young biotech targets that don't need to be forced into an early buyout impact this hypothetical M&A shift? This session will feature experienced voices explaining the public perspective for a potentially active year within pharma and biotech deal-making.

**MODERATOR:** **Ori Solomon**, *Partner, Morrison & Foerster LLP*

**PANELISTS:** **Andrew Gitkin**, *Managing Director and Co-Head of Healthcare Investment Banking, Raymond James*  
**Geoff Meyerson**, *CEO and Co-Founder, Locust Walk*  
**Kimberly Nearing**, *Venture Partner, BVCF Management, LTD.; Board of Directors, BayHelix*  
**Philip Ross**, *Vice Chairman, Healthcare Investment Banking, J.P. Morgan*  
**E. Eric Tokat**, *Partner, Centerview Partners LLC*



**1,200+**

**ATTENDEES**



**2,900+**

**PARTNERING MEETINGS**



**133**

**COMPANY PRESENTATIONS**



**650**

**REGISTERED INVESTORS**



**948**

**PARTICIPATING COMPANIES**



**33**

**COUNTRIES REPRESENTED**

## ► Navigating the New CFIUS Regulations for Investments with U.S. Partners

8:30-8:55 AM

**MODERATOR:** **Cameron Arterton**, *Vice President of Tax Policy, BIO*

**PANELIST:** **Richard C. Sofield**, *Partner, Wiley Rein LLP*

## ► Exploring Innovation in Cardiovascular Disease Therapeutics

9:00-9:55 AM

According to the World Health Organization, cardiovascular diseases are the leading cause of death globally. The American Heart Association estimates current direct costs for treatment of cardiovascular disease in the U.S. to be \$277 billion annually and expects costs to grow to \$655 billion by 2035. Venture capital investment for cardiovascular-focused therapeutic companies remains low relative to other therapeutic areas. Recently reported data from a few small biotechs suggest there is still activity in clinical development despite recent exits out of cardiovascular disease by larger pharmaceutical companies. Attend to learn more about companies in this space particularly in hypertension and heart failure, investor perspectives, and the latest data from BIO's report on cardiovascular therapeutics, the 5th volume in the series on highly prevalent chronic diseases.

**MODERATOR:** **TBD**

**PANELISTS:** **Grace E. Colón, PhD**, *President and CEO, Incarda Therapeutics, Inc.*  
**Jonathan Freeman, PhD**, *Senior Advisor, Blackstone Life Sciences*  
**Elliott Levy, MD**, *Senior Vice President, Global Development, Amgen*  
**Marc Semigran, MD**, *Senior Vice President, Medical Sciences, MyoKardia*  
**David Thomas**, *Vice President, Industry Research, BIO*



### Fireside Chats

10:00-10:55 AM



**Barbara Dalton, PhD**  
*Vice President, WWBD and Senior Managing Partner of Pfizer Ventures, Pfizer*



**Moderator**  
**Catherine Vorwald**  
*Director of Life Sciences, The Labs by Sterling Bay*

11:00-11:55 AM



**Ted W. Love, MD**  
*President and Chief Executive Officer, Global Blood Therapeutics*



**Moderator**  
**Alethia Young**  
*Managing Director, Head of Healthcare & Senior Biotech Research Analyst, Cantor Fitzgerald*

12:00-12:55 PM



**Evan Loh, MD**  
*Chief Executive Officer, Paratek Pharmaceuticals*

**Moderator**  
**Phyllis Arthur**  
*Vice President, Infectious Diseases & Diagnostics Policy, BIO*



## ► **Industry Approaches for Hiring and Developing an Inclusive Workforce**

**1:00-1:55 PM**

BIO in partnership with the Center for Talent Innovation will launch the first report on building an inclusive biotechnology workforce. Attend to learn more about diversity and inclusion best practices of companies at different stages of development. The session will also include an expert panel of executives with C-Suite and corporate board experience, investors, and diversity and inclusion professionals to provide insight on how to advance the biotechnology industry.

**MODERATOR:** **Brady Huggett**, *Business Editor, Nature Biotechnology*

**PANELISTS:** **Martin Babler**, *President and CEO, Principia Biopharma*  
**Ahtis Davis**, *Executive Director, Advancing Black Pathways, JPMorgan Chase*  
**Pooja Jain-Link**, *Executive Vice President, Center for Talent Innovation*  
**Sara Nayeem, MD**, *Partner, New Enterprise Associates*



## **Fireside Chat**

**2:00-2:55 PM**



**Michael M. Morrissey, PhD**  
*President and Chief Executive Officer, Exelixis*



**Moderator**  
**Asthika Goonewardene**  
*Managing Director, Senior Biotechnology Analyst, SunTrust Robinson Humphries*



**ONE**  
**PARTNERING™**  
Powered by BIO

### **BIO's One-on-One Partnering™ system**

is the interactive platform that allows you to increase your productivity, discover new investment and licensing opportunities, and expand your business potential worldwide.

- **Pre-schedule** 30-minute private 1x1 meetings
- **Source** potential collaborations and funding opportunities with an international audience
- **Communicate** directly with prospective investors and C-level executives in biotech and pharma
- **Search** company and investor profiles for potential business partnerships

Sponsored by H.C. Wainwright & Co.

## ► **Neuroscience at the Crossroads: Late Stage Brain Disorder Pipelines and Unmet Needs**

**3:00-3:55 PM**

In recent months, the exits of several large companies from the neuroscience space, optimistic turnarounds in clinical development in Alzheimer's disease, and the persistence of the opioid addiction crisis are signifying the true difficulties of developing drugs for the brain. With millions already suffering with CNS disorders and millions more expected to be diagnosed in the next decade, accelerated by the growing population of elderly, new treatment options are needed. What companies and which investors are rising to the challenge to bring treatments to the market? Hear from the biotech executives and investors involved in late-stage CNS drug development as they share insights into obstacles they've encountered and solutions they've developed to address the unmet needs in CNS disorders.

**MODERATOR:** **Jason Pitts, PhD**, *Principal, Private Equity, Sofinnova*

**PANELISTS:** **Roger Crystal**, *CEO, Opiant Pharmaceuticals*  
**Mark Gurney, MBA, PhD**, *Chairman & CEO, Tetra Therapeutics*  
**Ellen Lubman**, *Chief Business Officer, Impel NeuroPharma*  
**Christopher Missling, PhD**, *President and CEO, Anavex Life Sciences*  
**Jay Mohr**, *Chief Operating and Business Officer and Head of Commercial Development, AZTherapies, Inc.*

## ► **Market Outlook—Market Performance and IPO Class of 2020**

**4:00-4:55 PM**

With the close out of 2019 at record levels and 2020 in full swing, the biotechnology sector has proven itself to be a rewarding place for investors to devote their capital. The nature of the industry has also continually driven investors' focus toward the long-term potential, rather than short-term gains. While 2018 witnessed biotechnology companies going public at a frantic pace, 2019 brought more hesitation due to the pre- and post-IPO price volatility and the availability of robust private capital earlier in the company lifecycle. This access to capital has allowed companies to maintain focus on the R&D product pipeline and build mature enterprises with established clinical results prior to accessing the public markets. With a strong market economy and healthy portfolio of large, private companies, it begs the question of whether the overall market will experience a cooling off period in 2020 or if we are at the beginning of a long-term growth cycle? This session will examine the path forward while highlighting the availability of quality targets in the market.

**MODERATOR:** **John Vandermosten**, *Biotechnology Analyst, Zacks Research*

**PANELISTS:** **Noël Brown**, *Managing Director, Cantor Fitzgerald*  
**James Cappuccio**, *Managing Director, Investment Banking, H.C. Wainwright & Co., LLC*  
**Jeff Galvin**, *CEO and Co-Founder, AGT*  
**Jorge Ramirez**, *Principal, H.I.G. BioHealth Partners*  
**Jennifer Sheng**, *Managing Director, Healthcare Equity Capital Markets, Citigroup Global Markets*







# Executive Training Programs

## BIO Executive Leadership Course: Applying Game Theory to Negotiations and Business Development: Spotlights on Deal Making and the Elevator Pitch

Offered in conjunction with the BIO CEO & Investor Conference for an additional fee. To RSVP, please email [register@bio.org](mailto:register@bio.org) with "Course: Applying Game Theory" in your subject line.

**WEDNESDAY, FEBRUARY 12 • 8:30 AM-1:00 PM**

This workshop is designed for executives who wish to enhance their skills in negotiations, influencing and decision making. The uniqueness of this advanced workshop is to leverage the combination of these skills. You will not only learn to anticipate but also to plan strategically ahead by making use of insights from game theory, with the aim to improve decision making and negotiation outcomes. The learnings from game theory will be applied to real-life pharma/biotech cases.

The Course will feature interactive sessions, facilitated discussions and in-class exercises, this workshop is primarily based on real-life pharma/biotech cases. The cases will be analyzed by uniquely combining the ideas of game theory and advanced business development practice.

### ► Learning Objectives

By participating in this workshop, you will learn how to:

- Improve your decision making by acquire a systematic framework for decision making using Game Theory.
- Achieve better negotiation results by applying advanced negotiation techniques.
- Enhance your influencing skills by applying learnings from the BD practice.
- Master new strategies to steer business interactions.

### ► Faculty



**Harm-Jan Borgeld, CSAP, PhD**  
*Head Alliance Management  
Merck KGaA, Darmstadt, Germany*



**Stefanie Schubert, CA-AM, PhD**  
*Professor of Economics  
SRH, University Heidelberg*

### ► Topics Covered

#### Decision making

- Successful CEOs decision making
- Parallel option assessment
- Influencers of rationale decision making

#### Negotiations

- First and second offer strategies
- Multiple Equivalent Simultaneous Offers
- Know when not to negotiate
- The Right Rationale
- Sources of Negotiation Power
- Group negotiations

#### Influencing

- Traits of success influencers
- How to weaken your opponent's strategic moves
- Influencing in the business environment

# 2020 Presenting Companies\*

**15** New for 2020:  
presentations from NYCEDC  
supported biotechs

## Cardiovascular

Caladrius Biosciences, Inc. (NASDAQ:CLBS)  
Deck Therapeutics

## CNS/Neurological

Amygdala Neurosciences, Inc.  
APRINOIA Therapeutics  
AZ Therapeutics, Inc.  
Brainstorm Cell Therapeutics (NASDAQ:BCLI)  
Cerevance  
CytoDel  
Engage Therapeutics  
FSD Pharma (NASDAQ Capital Market:HUGE)  
MetVital, Inc.  
NeuroRx, Inc.  
NEWRON PHARMACEUTICALS SPA  
(SIX, XETRA:NWRN, NP5)  
Origenis GmbH  
Oryzon Genomics SA (Spanish Exchange:ORY)  
Pipeline Therapeutics, Inc.  
Sound Pharmaceuticals  
Tonix Pharmaceuticals (NASDAQ:TNXP)

## Contract Manufacturing Organization

JHL Biotech Inc.

## Diagnostics

Breakthrough Genomics  
Immunis.AI  
Molecular Theranostics, LLC  
Oriol Research Therapeutics  
Quadrant Biosciences Inc.  
Sengenics Corporation Pte Ltd

## Digital Health

AiCure  
Gero  
MedicaSafe  
PainQx

## Gastrointestinal

Cernostics  
Intract Pharma  
Synthetic Biologics, Inc. (NYSE American:SYN)

## Gene/Cell Therapy

Actinium Pharmaceuticals, Inc.  
(NYSE AMEX:ATNM)  
AIVITA Biomedical, Inc.  
Cytonus Therapeutics Inc.  
Cytovia Therapeutics  
Glycostem Therapeutics BV  
Mogrify Ltd  
Olipass Corp (KOSDAQ:KQ244460)  
OriCiro Genomics  
SmartPharm Therapeutics  
TargetGene Biotechnologies  
Thoth Science Inc.  
XyloCor Therapeutics, Inc.

## Immunology

Ilya Pharma  
IMV Inc. (NASDAQ:IMV)  
Landos Biopharma  
Pattern Pharma Inc.  
Serimmune, Inc.  
Sparrow Pharmaceuticals  
Step Pharm

## Infectious Diseases

Enesi Pharma Limited  
Ichor Biologics  
Summit Therapeutics (NASDAQ:SMMT)  
VBI Vaccines Inc. (NASDAQ:VBIV)  
Venatorx Pharmaceuticals

## Inflammation

Eleusis

## Metabolic Diseases

CohBar (NASDAQ:CWBR)  
Oxidien Pharmaceuticals, LLC  
Praetego Inc.

## Multiple Therapeutics

Altimmune Inc. (NASDAQ:ALT)  
Anima Biotech Inc  
Aptorum Group Limited (NASDAQ:APM)  
BioXcel Therapeutics (NASDAQ:BTAL)  
Protalix Biotherapeutics  
(American: NYSE:PLX)  
Samus Therapeutics, Inc.  
Soligenix, Inc. (NASDAQ:SNGX)

## Non-Profit/Patient Advocacy Group

Muscular Dystrophy Association

## Oncology

AIMM Therapeutics  
AnHeart Therapeutics (Hangzhou) Co., Ltd.  
Aptose Biosciences Inc. (NASDAQ:APTO)  
ARJUNA Therapeutics  
Atossa Therapeutics (NASDAQ:ATOS)  
Atreca, Inc. (NASDAQ:BOEL)  
Boundless Bio Inc.  
Cancer Prevention Pharmaceuticals, Inc.  
CEL-SCI Corporation (NYSE American:CVM)  
Concarlo Holdings, LLC  
Cyclacel Pharmaceuticals, Inc.  
(NASDAQ:CYCC, CYCCP)  
eFFECTOR Therapeutics  
ENB THERAPEUTICS  
Envisagenics  
EpiVax Oncology, Inc.  
e-Therapeutics plc (AIM:ETX.L)  
Glycantis Inc.  
Greenwich LifeSciences  
ImmunoMet Therapeutics  
ImmunSYS™ Inc.  
Inflection Biosciences Ltd  
Kineta, Inc.  
Kymeris  
Libera Bio (EO-Capital LLC)  
MAIA Biotechnology, Inc  
MaxCyte, Inc. (LSE - AIM:MXCT)  
Oragenics, Inc. (NYSE:OGEN)  
PDS Biotechnology (NASDAQ:PDSB)  
Phanes Therapeutics, Inc.  
PHD Biosciences  
Phosplatin Therapeutics  
Qwixel Therapeutics LLC  
RubrYc Therapeutics, Inc.  
Salarius Pharmaceuticals (NASDAQ:SLRX)  
Starton Therapeutics  
Synthis  
Teon Therapeutics, Inc.

Trovagene, Inc. (NASDAQ:TROV)  
VBL Therapeutics (NASDAQ:VBLT)  
VerImmune

## Ophthalmology

Clearside Biomedical Inc (NASDAQ:CLSD)  
Emerald Bioscience, Inc. (OTCQB:EMBI)  
EyeGate Pharmaceuticals, Inc.  
(NASDAQ:EYEG)  
Outlook Therapeutics, Inc. (NASDAQ Capital  
Markets:OTLK)  
Ripple Therapeutics

## Orphan/Rare Diseases

Amplix Pharmaceuticals  
Bioasis Technologies Inc. (TSX Venture:  
BTI, OTCQB: BIOAF)  
Catalyst Pharmaceuticals, Inc.  
(NASDAQ:OPRX)  
Gain Therapeutics SA  
Liminal BioSciences Ltd (NASDAQ &  
TSX:LMNL)  
Mucpharm  
Rezolute (OTC:RZLT)  
Zikani Therapeutics

## Other

Evonetix Ltd  
Goldilocks Therapeutics, Inc.  
Kintai Therapeutics  
Rockwell Medical (NASDAQ:RMTI)  
twoXAR

## Pain Management

CerSci Therapeutics

## Platform for Therapeutics

Asimov  
Dyadic International, Inc. (NASDAQ:DYAI)  
Novadip Biosciences  
Oramed Pharmaceuticals (NASDAQ:ORMP)  
Panorama Medicine  
ReForm Biologics LLC

## Regenerative Medicine

Celavie Biosciences LLC  
Matricelf

## Reproductive/Sexual Health

Daré Bioscience (NASDAQ:DARE)

## Respiratory

aTyr Pharma (NASDAQ:LIFE)

\*as of January 21, 2020

## BUZZ of BIO Winners

**BrainStorm Cell Therapeutics**  
*Public Therapeutic Company Winner*

**AZ Therapeutics**  
*Private Therapeutic Company Winner*

**Breakthrough Genomics**  
*Diagnostics & Beyond Winner*













# 2020 Participating Investors\*

3E Bioventures	BioSense Global	ETP Global Fund	JM Cohen & Co.
3iFund	Biotech Alliances International	EVOLUTION Life Science Partners	Johnston Associates
A C Binder	Biotech Investment Group	Executive Forum Angels	J.P. Morgan
Accelmed Partners	Black Diamond Advisors	Exome Asset Management	K2 HealthVentures
Aceras Partners	Blue Rock Capital Advisors	Fannin Innovation Studio	Kalka Fund
Acorn Bioventures	Bohe Angel Fund	FC Capital	Krensavage Asset Management
Acuitas Capital	Bojian Capital	First Island Capital	Ladenburg Thalman
Aditum Bio	Brace Pharma Capital 	First Seafront Fund Management	Laidlaw Venture Partners
Adjuvant Capital 	Bridge Bank	FMG Ventures	Life Sciences Greenhouse of
Affinity Asset Advisors	Brock Capital Group	Fortress Biotech 	Central PA
AFUND	Brookline Capital Markets	Fountain Healthcare Partners	LifeNet Health
AIG	Bryan, Garnier & Co.	Foxhill Asset Management	LifeScience EquityPartners
Aisling Capital LLC	BTIG	Franklin Global Partners	LifeTech Capital
Aleph Capital	Canaccord Genuity	Frigate Capital Management	Lincoln Park Capital
Alignment Ventures	Cantor	Fujifilm Capital Management	Lions Bay Capital
Alliance for Aging Research	Capital Family Office 	Gagnon Securities	Livingston
Alliance for Cancer	CatoBioVentures	Global Founders Capital	LSWorks
Gene Therapy 	Caxton Alternative Management	Global Neurohealth Ventures 	LumeBio
Alnitak Capital	Chaperone Investment	Golden Eagle Capital Advisors	Lumira Ventures
Amplitude	Chardan Capital Markets	Goldwater Asset Management	Lyfe Capital
Andreessen Horowitz	Charlestown Capital	Good Health Capital	Madryn Asset Management
Anson Funds	Chartwell	Grey Sky Venture Partners 	Magid Family Office
Aracle Capital LLC	Chronon Capital	H.C. Wainwright & Co.	Maxim Group
ARCH Venture Partners	Church Pension Fund	H.I.G. BioHealth Partners <span>&gt;</span>	MAZ Capital Advisors
Arix Bioscience	CJ Seligman & Co.	H.I.G. Capital Management	MedPro Investors
Armistice Capital	CLI	Hannol Ventures 	Merlin Nexus
Arsenal Capital Partners	Cowen Healthcare Investments	Harbin Pharmaceutical Group	Mid Atlantic Bio Angels
Ascendant Capital Markets	Cowin Venture	Harvard Investors Group	MIT Alumni Angels of
Ashford Capital Management	Crescent Capital Ventures	Health Innovative Technology	Northern California 
Aspire Capital	Crosswave Management 	Corporation	Mitsui & Co. Global Investment
Asset Management Ventures	CRV	HealthCare Royalty Partners	
Astellas Pharma US	CSC Leasing 	HEDA Ventures	Mizuho Corporate Bank
Astellas Venture Management	CTI Capital Gestion Inc.	Hercules Capital 	Mizuho Securities
	CTTQ Pharmaceutical Group	Hibiscus Bioventures	Morgan Capital
Astute Capital	CyberMed Holdings	HighCape Capital	Mountain Brook Capital
ATEM Capital	Dabar Investment Associates	Highland Capital Management	MV Corp Services
Atheneos Ventures	DB Capital	Horizon Technology Finance	MVP Capital Partners
AUGC	Deca Ventures	Hudson East Capital	National Holdings Corporation
Aurora	Deerfield Management Company	Hudson Square Capital	NauVista Capital Management
Ayrton Capital	DEFTA Partners	Hyperplane VC	NCL Technology Ventures
Baidu	Delaware Innovation Space	Inbio Ventures	Needham & Co.
Bank of America Merrill Lynch	Deltec Bank	Ingenio Therapeutics / Mayewell	Network 1 Financial Securities
Barclays	Delwar Capital Management	Capital	Neurotrope, Inc.
Bathala Capital	Deutsche Bank	InMed Pharmaceuticals	New Jersey Investment Division
Beacon Capital	DHVC 	Innovent Biologics	New York Angels
Berenberg Capital Markets	District 2 Capital	Integrium	Newburgh Bay Capital
Bifrost Capital	Douglas C. Lane & Associates	inThought Research	NGN Capital
Bigger Capital Fund	DTB Capital Management	Intuitive	Noble Equity Fund
BIMA Capital	Dynamk Capital 	Inukshuk Capital	Northlea Partners
BioAdvance	E Squared Asset Management	ISAR Capital Management	Novatio Ventures
Biocoast Capital	E Squared Capital	J.H. Darbie & Co.	Novo Ventures
BiolDEA	Easton Capital	J.W. Childs Associates	NSIP
Bioldeations	Edgewood Management	Janney Montgomery Scott	NYC Medtech/Perselson
BiolInnovation Capital	EG Capital Advisors	Jefferies	Oasis Capital
Biondo Investment Advisors	Ensconce Capital	Jiangsu Hengrui Medicine Co.	Oberland Capital
Bios Partners	Esousa Holdings	Jina Ventures	Omega Funds



Thank you to our 2020 BIO Triple Crown Partners, those having partnered in the most recent cycle of BIO's triple crown of BD & Investor events, BIO Investor Forum, 1x1@JPM, and BIO CEO & Investor Conference.

## 2020 Participating Investors (continued)

Oppenheimer & Co.	Revach Fund	SPRIM Ventures 	Unterberg Capital
Opto Capital Group	RHK Capital 	SR One	Upstream Partners
Oracle Partners	Robert W. Baird & Co.	Starlink Capital	V2m Life Sciences Fund
Orange Grove Bio	Rolin	Stonehenge Capital	ValQuest
OrbiMed Advisors	Rosetta Capital	Strathspey Crown 	Varana Resource Funds
Orchard View Capital Advisors	Roth Capital Partners	Sun Pharmaceuticals	Vector Point Ventures
Otsuka Pharmaceutical Co. 	RW Baird	SunTrust Robinson Humphrey	Vector Resource Funds
Oxford Finance	Sagard Holdings	Surveyor Capital	Vista Capital Advisors
Pacific Western Bank	Sandhill Angels 	Taiho Ventures	Vista Point Capital
Pappas Capital	Santen Pharmaceutical Co.	Tang Capital Management	Voya Financial
Park Ave. Capital Management	Sarissa Capital Management	Tectonic Capital	W Global Capital Limited 
International	Satter Medical Technology	Terra Stone Capital	Wallachbeth Capital
Parkman Healthcare Partners	Partnership	The Abraham Group	WBB Securities
Parkville Advisors	SDIC Fund Management	The Anson Group	Western International
Peak One Investments	Second Line Capital Management	The Astrologers Fund	Westlake Ventures
Perseverance Capital	Sector Asset Management	The Benchmark Company	Wexford Capital
Advisors 	Serrado Capital	The Center for Performance	Wick Capital Partners
Petrichor Healthcare Capital	Shanghai Henlius Biotech	Investing	Wolpert Associates
Management	Shaw Strategic Capital	The Engine	Xeraya Capital Life Venture 
Pharmakon Advisors	Signature Bank	The Leukemia & Lymphoma	Xerion Investments
Piper Sandler	Simcere Pharmaceutical Group	Society	YA Global
Premier Partners	Simrx Advisors	The Lind Partners	Yale University, Office of
Prevail Partners 	Sio Capital Management	Think Equity	Cooperative Research
Princeton Biopharma	Sky Ventures Group	Tokyo Stock Exchange	YILGA Management Services
Prism Biomedical Research	Smilegate Investment	Tosoh USA 	Young America Capital
Promethean Capital Group	Sofinnova Ventures	Treehill Principal Strategies	Zacks Small Cap Research
Quan Capital	Solar Capital Partners	Tri-Medix	Zeniths Capital
Raymond James	Sound Affects	Tryphon Capital Advisors	ZJ Future
Remsen Investors	Special Situations Funds	University of Notre Dame	

\*as of January 29, 2020



Thank you to our 2020 BIO Triple Crown Partners, those having partnered in the most recent cycle of BIO's triple crown of BD & Investor events, BIO Investor Forum, 1x1@JPM, and BIO CEO & Investor Conference.






# 2020 Participating Companies\*

3E Bioventures	Ascendia Pharmaceuticals	Boundless Bio 	CTTQ Pharmaceutical Group
3i Fund	Ascendant Capital Markets	Brace Pharma Capital	CV6 Therapeutics
A C Binder Corp	Ashford Capital Management	BrainStorm Cell Therapeutics	CyberMed Holdings
Ab Studio	Ashvattha Therapeutics	Breakthrough Genomics 	Cybrena Therapeutics
AbbVie 	Asimov	Brex	Cyclacel Pharmaceuticals
Accelmed Partners	Aspire Capital	Bridge Bank	Cytodel
Aceras Partners	Asset Management Ventures	Bristol-Myers Squibb Company	Cytosus Therapeutics
Achillion Pharmaceuticals	Astellas Pharma US	Brock Capital Group	Cytovia Therapeutics
Acorn Bioventures	Astellas Venture Management	Brookline Capital Markets	Da Volterra 
Actinium	Astute Capital	Bryan, Garnier & Co.	Dabar Investment Associates
Acuitas Capital Family Office	ATEM Capital	BTIG	Daré Bioscience
Aditum Bio	Atheneos Ventures	BVCF	DB Capital
Adjvant Capital	Atossa Genetics	BW Therapeutics	Deca Ventures
Aetion	Atreca	Caladrius Biosciences	Deck Therapeutics
Affinity Asset Advisors	aTyr Pharma	California Life Sciences	Decoy Biosystems
AFUND	AUGC	Association 	Deerfield Management Company
Ai Cure Technologies	Aurora Capitals	Canaccord Genuity	Delaware Innovation Space
AIG	Avalere Health	Cancer Prevention	DelMar Pharmaceuticals
AIMM Therapeutics	Avenue Therapeutics	Pharmaceuticals	Deltac Bank
Aisling Capital	Ayrton Capital	Cantor	Delwar Capital Management
AiVita Biomedical	Azitra	Capital Family Office	DepYmed
Aleph Capital	AZTherapies	Cardinal Health	Deutsche Bank
Alexandria Venture Investments	Baidu	Catalyst Pharmaceuticals	DHVC
Alignment Ventures	Baird	Cato BioVentures	District 2 Capital
Alliance for Aging Research	Bank of America Merrill Lynch	Caxton Alternative Management	Doha Institute For Graduate
Alliance for Cancer Gene Therapy	Barclays	Cedrus Group	Studies
Alnitak Capital	Bathala Capital	Celavie Biosciences	Douglas C. Lane & Associates
Alpha Cancer Technologies 	Beacon Capital	Cell Care Therapeutics	Drusolv Therapeutics
Alpine Immune Sciences 	Bellerophon Therapeutics	Celmatix	DTB Capital Management
Altimune	Berenberg Capital Markets	CEL-SCI Corporation	Dyadic International 
ALTuCELL	Berlin Partner für Wirtschaft und	Centerview Partners	Dynamk Capital
Alveo Technologies	Technologie GmbH	Cerevance	Dyve Biosciences 
American Gene Technologies	Bifrost Capital	Cernostics	E Squared Capital Management
International 	Bigger Capital Fund	CerSci Therapeutics	Easton Capital
Amnicell	BIMA Capital	Chaperone Investment	Edgewood Management
Amplitude Ventures	Bioadvance-The Biotech	Chardan Capital Markets	eFFECTOR Therapeutics
Amplix Pharmaceuticals	Greenhouse Corp of	Charlestown Capital	EG Capital Advisors
Amygdala Neurosciences	Southeastern PA	Chartwell	Eleusis
Anavex Life Sciences	Bioasis Technologies	ChemioCare	Eli Lilly and Company
Andreessen Horowitz	BioCentury	Chronon Capital	Elox Pharmaceuticals
AnGes	Biocept	Chubb 	Emerald Bioscience
AnHeart Therapeutics (Hangzhou)	Biocoast Capital	Church Pension Fund	ENB Therapeutics
Anima Biotech	BiolDEA	CJ Seligman & Co.	Encore Advisory
Anson Funds	Bioldeations	Clearside Biomedical	Enesi Pharma
Aon Risk Solutions	Bioindustry Association (BIA)	CLI Ventures	Engage Therapeutics
Apex-Brasil - Brazilian Trade and	BioInnovation Capital	Clinical Network Services (Cns)	Engrail Therapeutics
Investment Promotion Agency	BioLineRx	CODA Biotherapeutics	Ensconce Capital
Aprinoia Therapeutics	BioMarker Strategies	CohBar	Envisagenics
Aptorum Group	Biondo Investment Advisors	Concarlo Holdings	EpicientRx
Aptose Biosciences	Bios Partners	Consulate General of Lithuania	EpiVax Oncology
Aracari Biosciences	BioSense Global	Correlia Biosystems	Equilibrium
Aracle Capital	Biotech Alliances International	Cowen Healthcare Investments	Esousa Holdings
Arch Biopartners	Biotech Investment Group	Cowin Venture	E-Therapeutics
Arch Venture Partners	BioVersys AG	CreActive Health	ETP Global Fund
Arena Pharmaceuticals	BioXcel Therapeutics	Crescent Capital Ventures	Eupraxia Pharmaceuticals
Arix Bioscience	Black Diamond Advisors	Cristal Therapeutics	EVOLUTION Life Science Partners
ARJUNA Therapeutics	Blue Rock Capital Advisors	Crosswave Management	Evonetix
Armistice Capital	Bloomberg Intelligence	CRV	EVQLV
Arsenal Capital Partners	Bohe Angel Fund	CSC Leasing	Executive Forum Angels
Aruvant Sciences	Bojian Capital	CTI Capital Gestion	Exome Asset Management



Thank you to our 2020 BIO Triple Crown Partners, those having partnered in the most recent cycle of BIO's triple crown of BD & Investor events, BIO Investor Forum, 1x1@JPM, and BIO CEO & Investor Conference.

## 2020 Participating Companies (continued)

EyeGate Pharmaceuticals	Hyperplane VC	Leap Therapeutics	NauVista Capital Management
Fannin Innovation Studio	Ichor Biologics	Libera Bio	Navigen Pharmaceuticals
FC Capital	IDA Ireland	Life Science Connect	NB Health Laboratory Co.
First Island Capital	Ilya Pharma	Life Sciences Greenhouse of Central PA	NCL Technology Ventures
First Seafront Fund Management	Immunis.AI	LifeNet Health	NDA Group
First Wave	ImmunoMet Therapeutics 	LifeScience EquityPartners	Needham & Co.
FMG Ventures	ImmunSYS	LifeTech Capital	Nektar Therapeutics
Fortress Biotech	Impel NeuroPharma	Lilly Asia Ventures	Network 1 Financial Securities
Fountain Healthcare Partners	IMV 	Liminal BioSciences	Neumentum 
Foxhill Asset Management	Inbio Ventures	Lincoln Park Capital	Neurogenesis
Franklin Global Partners	InCarda Therapeutics	Lions Bay Capital	NeuroRx
Frigate Capital Management	Inflection Biosciences	Lipella Pharmaceuticals	Neurotrope
FSD Pharma	Informa	Livingston	New Enterprise Associates (NEA)
Fujifilm Diosynth Biotechnologies	Ingenio Therapeutics, Inc. / Mayewell Capital	Locust Walk	New Jersey Investment Division
Gagnon Securities	InMed Pharmaceuticals	LSWorks	New York Angels
Gain Therapeutics	INmune Bio	LumeBio	Newburgh Bay Capital
GBA Group Pharma	Innovent Biologics	Lumira Ventures	NewLink Genetics
Gedeon Richter	Integrium	Lyfe Capital	Newron Pharmaceuticals
Geistlich Pharma North America	InterRNA Technologies	MacDougall Biomedical Communications 	NGM Biopharmaceutical
Gel4Med 	Inthera Bioscience	Madison Global Partners	NGN Capital
Genfit SA	inThought Research	Madryn Asset Management	Nikon Instruments
Genisphere	Intract Pharma	Magid Family Office	Nirogyone Therapeutics
Georgia, USA	Intuitive	MAIA Biotechnology	Noble Equity Fund
Gero PTE	Inukshuk Capital	Marcum	Northlea Partners
Global Neurohealth Ventures	iQure Pharma	Massive Bio	Notogen
Glycomine	Ironshore Pharmaceutical & Development	Matricelf	Novadip Biosciences
Glycostem Therapeutics	ISAR Capital Management	MaxCyte	Novatio Ventures
Glystantis	J.P. Morgan	Maxim Group	Novice Therapeutics
Gnomegen	J.W. Childs Associates	MAZ Capital Advisors	Novo Ventures (US)
Golden Eagle Capital Advisors	Janney Montgomery Scott	MediSieve Limited	Now Biopharma
Goldilocks Therapeutics	Janssen R&D	MedPro Investors	NSIP
Goldwater Asset Management	Jefferies	Merlin Nexus	NYC Builds Bio+
Good Health Capital	Jefferson Pharmaceuticals	MetVital 	NYCMedtech/Perselson
Government of Quebec	JH Darbie & Co.	Microba	Oasis Capital
Great Bay Bio Limited	JHL Biotech	MimiVax	Oberland Capital Management
Greater Zurich Area Ag	Jiangsu Hengrui Medicine Co.	Mission Pharmacal	Oligomerix
GreenSky Capital	Jina Ventures	MIT Alumni Angels of Northern California	OliPass
Greenwich LifeSciences	JM Cohen & Co.	Mitsui & Co. Global Investment Inc.	Omega Funds
Grey Sky Venture Partners	Johnston Associates	Mizuho Corporate Bank	Oncodesign
H.C. Wainwright & Company	J.P. Morgan	Mizuho Securities	Oncolyze
H.I.G. BioHealth Partners	K2 Health Ventures	Mizuho Securities USA	Onconova Therapeutics
H.I.G. Capital Management	Kalka Fund	Modra Pharmaceuticals	OncoSec Immunotherapies
Hannol Ventures	Katena Oncology	Mogrify Limited	ONL Therapeutics
Harbin Pharmaceutical Group	Keynote Coaching	Molecular Theranostics	Ontario Brain Institute
Harpoon Therapeutics	Kineta	Morgan Capital	Opiant Pharmaceuticals
Harvard Investors Group	Kintai Therapeutics	Morrison & Foerster	OPIS
Headland Strategy Group	Kisoji Biotechnology	Mount Sinai School of Medicine	Oppenheimer & Co.
Health Innovative Technology Corporation	Kissei America	Mountain Brook Capital	Opto Capital Group
HealthCare Royalty Partners	Kitov Pharma	Mucpharm	Opus Biotech Communications
HEDA Ventures	Korea Drug Development Fund	Muscular Dystrophy Association (MDA)	Oracle Partners
Hercules Capital	Krensavage Asset Management	MV Corp Services	Oragenics
Hibiscus Bioventures	Kymeris 	Nascent Biotech	Oramed Pharmaceuticals
HighCape Capital	Ladenburg Thalmann	National Heart, Lung, and Blood Institute	Orange Grove Bio
Highland Capital Management	Laidlaw Venture Partners	National Holdings Corporation	OrbiMed Advisors
Histogen 	Landos Biopharma		Orchard View Capital Advisors
Hitech Health	Lauren Sciences		Orgenesis
Horizon Technology Finance	LaVoieHealthScience		OriCiro Genomics
Hudson East Capital	Leading BioSciences		Origenis GmbH
Hudson Square Capital			Oryzon Genomics
			Otsuka Pharmaceutical Co.



Thank you to our 2020 BIO Triple Crown Partners, those having partnered in the most recent cycle of BIO's triple crown of BD & Investor events, BIO Investor Forum, 1x1@JPM, and BIO CEO & Investor Conference.



# 2020 Participating Companies (continued)

Outlook Therapeutics	RHK Capital	Stalica	twoXAR
Ovid Therapeutics	RHO	Starlink Capital	University of Exeter
Oxford Finance	Ripple Therapeutics	Stemsynergy Therapeutics	University of Notre Dame
Oxidien Pharmaceuticals	RMJ Holdings	Step Pharma	University of Texas, MD Anderson
OxStem Limited	Rockwell Medical	Sterling Bay	Cancer Center
Pacific Western Bank	Roher/Sprague Partners	Stonehenge Capital	Unterberg Capital
PainQx	Rolin	Strathspey Crown	Upstream Partners
Panorama Medicine	Rosetta Capital	Summit Therapeutics	V2m Life Sciences Fund
Pappas Capital	Roth Capital Partners	Sun Pharmaceuticals	ValQuest
Paras Biopharmaceuticals	Rubryc Therapeutics	SunTrust Robinson Humphrey	Varana Capital
Finland Oy 	Rumi Scientific California	Surveyor Capital	Vaximm
Paratek Pharmaceuticals	Russo Partners	Sutro Biopharma 	VBL Therapeutics
Park Ave. Capital Management	RW Baird	Swiss Business Hub USA	Vector Resource Funds
International	Sagard Holdings	SynDevRx	VenatoRx Pharmaceuticals
Parkman Healthcare Partners	Salarius Pharmaceuticals	Syneos Health	VerImmune
Parkville Advisors	Samus Therapeutics	Synlogic	Verum Diagnostics
Pattern Pharma	Sandhill Angels	Synthetic Biologics 	Vida Strategic Partners
PDS Biotechnology	Sandoz	Synthis	viDA Therapeutics
Peak One Investments	Sanofi US	Taiho Ventures	Vida Ventures
Perseverance Capital Advisors	Santen Pharmaceutical Co.	Tang Capital Management	Vigeo Therapeutics
Petrichor Healthcare Capital	Sarissa Capital Management	TargetGene Biotechnologies	Viking Therapeutics
Management	Satter Medical Technology	TenNor Therapeutics	Vincere Biosciences
Pfizer	Partnership	Teon Therapeutics	Viracta Therapeutics
PhagoMed Biopharma GmbH	SBI JI Innovation Fund	Terra Stone Capital	Vista Capital Advisors
Phanes Therapeutics 	Scancell	Terran Biosciences	Vista Point Capital
Pharma Intelligence	Scynexis	Tetra Therapeutics	Vita Therapeutics
PharmaDirections	SDIC Fund Management	TFF Pharmaceuticals	Voya Financial
Pharmakon Advisors	Second Line Capital Management	The Abraham Group	Vyome Therapeutics
PHD Biosciences	Sector Asset Management	The Anson Group	W Global Capital
Phosplatin Therapeutics	SEngine Precision Medicine 	The Astrologers Fund	Wallachbeth Capital
Pipeline Therapeutics	Serimmune 	The Benchmark Company	WBB Securities
Piper Sandler	Serrado Capital	The Center for Performance	Western International
Polynoma	Servier	Investing	Westlake Ventures
POP Biotechnologies	Shanghai Henlius Biotech	The Engine	Westwood Therapeutics
Praetego	ShareVault	The Leukemia & Lymphoma	Wexford Capital
Premier Partners	Shaw Strategic Capital	Society	Wick Capital Partners
Prevail Partners	Shawn Tomasello Consulting	The Lind Partners	Wolpert Associates
Princeton Biopharma	Shinkei Therapeutics 	The Money Channel	Women In Bio
Principia Biopharma	Signature Bank	TheraTarget	X-Biotix Therapeutics
Prism Biomedical Research	Simcere Pharmaceutical Group	Think Equity	Xeraya Capital Life Venture
Promethean Capital Group	Simrx Advisors	Thoth Science	Xerion Investments
Protalix Biotherapeutics	Sio Capital Management	Tiberend Strategic Advisors	XyloCor Therapeutics
Quadrant Biosciences	Sky Ventures Group	TnA Therapeutics	YA Global
Quan Capital	SmartPharm Therapeutics	Tokyo Stock Exchange	Yale University, Office of
RallyBio	Smilegate Investment	TONIX Pharmaceuticals	Cooperative Research
Raymond James & Associates	SMP Communications	Torreya	Yamo Pharmaceuticals
RBW Consulting	Sofinnova Ventures	Tosoh USA	YILGA Management Services
Redx Pharma	Solar Capital Partners	Treehill Principal Strategies	Young America Capital
ReForm Biologics	Soligenix	TrialSpark	Zacks Small Cap Research
Remsen Investors	Sound Affects	Tri-Medix	Zeniths Capital
Rescue Hearing	Sparrow Pharmaceuticals	TriSalus Life Sciences	Zikani Therapeutics
Revach Fund	Special Situations Funds	Trovagene	ZJ Future
Rezolute	SPRIM Ventures	Tryphon Capital Advisors	
RG+A	SR One	Tulane University 	

\*as of January 29, 2020



Thank you to our 2020 BIO Triple Crown Partners, those having partnered in the most recent cycle of BIO's triple crown of BD & Investor events, BIO Investor Forum, 1x1@JPM, and BIO CEO & Investor Conference.

# Sponsors

## DOUBLE HELIX SPONSORS



Bristol-Myers Squibb



## SUPPORTING BANK SPONSORS



## CONFERENCE SPONSORS



## MEDIA PARTNERS



## SUPPORTING ORGANIZATIONS





# 2020 Advisory Committee



**Jennifer Hawks Bland**

Chief Executive Officer  
NewYorkBIO



**Janice Bourque**

Managing Director,  
Life Sciences  
Hercules Technology  
Growth Capital



**Aoife Brennan,  
MB, CHB**

President and CEO  
Synlogic



**Noël Brown**

Managing Director  
Cantor Fitzgerald



**Vered Caplan**

CEO and Director  
Orgenesis Inc.



**Jie D'Elia, PhD**

Vice President, Business  
Development, Hematology,  
Cell Therapy, and  
Translational Medicine  
Bristol-Myers Squibb



**Peter Fong, PhD**

Senior Managing Director,  
Head Of Company Creation  
RTW investments



**Andrew Gitkin**

Managing Director, Co-Head of  
Healthcare Investment Banking  
Raymond James



**Lan Huang, PhD**

Co-Founder, Chairman & Chief  
Executive Officer  
BeyondSpring



**Anna Kazanchyan, MD**

Founder & CEO  
Sagmos Therapeutics



**Ciara Kennedy, PhD**

President and CEO  
Amplix



**Jonathan Leff**

Partner  
Deerfield Management  
Chairman  
Deerfield Institute



**Lucy Lu, MD**

President and CEO  
Avenue Therapeutics



**Bibhash  
Mukhopadhyay, PhD**

Principal  
New Enterprise  
Associates



**Sara Nayeem, MD**

Partner  
New Enterprise  
Associates



**Kimberly Nearing**

Venture Partner  
BVCF Management, LTD.  
Board of Directors  
BayHelix



**Kuldeep Neote, PhD**

Vice President  
External Innovation  
Eli Lilly and Company



**Susan Peschin, MHS**

President and  
Chief Executive Officer  
Alliance for Aging  
Research



**Dennis J. Purcell**

Founder and Senior Advisor  
Aisling Capital



**Yasmeen Rahimi, PhD**

Managing Director & Senior  
Research Analyst, Co-Head of  
Biotechnology Research  
ROTH Capital Partners



**Stephen Ritoch**

Chairman and Chief  
Executive Officer  
Blaise Group  
International



**Philip Ross**

Vice Chairman, Healthcare  
Investment Banking  
J.P. Morgan



**Mahendra Shah, PhD**

Managing Director  
Vivo Capital



**Jennifer Sheng**

Managing Director, Healthcare  
Equity Capital Markets  
Citigroup Global  
Markets



**Marco Taglietti, MD**

President and Chief  
Executive Officer  
SCYNEXIS

# Registration & Housing Information

BIO offers a number of ways to conference attendees to save money on their registration fees.

**Discounted rates apply to the following:**

- ▶ Companies bringing more than three employees.
- ▶ Academic, government and non-profit institutions.
- ▶ Service providers suppliers.

Visit **bio.org/ceo**  
to view rates.

Qualified institutional and venture investors are eligible for complimentary registration.

BIO has a block of discounted hotel rooms for BIO CEO attendees. To take advantage of this special rate, contact the hotel no later than **January 28th**.

**New York Marriott Marquis**

1535 Broadway, New York

**212.398.1900**

## Contact BIO Registration

Email: **registration@bio.org**

Telephone: **+1.202.962.6655**